November 5

Comments

Transcription

November 5
Organized by:
Support:
Official Travel Agency:
blumar.com.br
Official Travel Agency:
COMUNICAÇÃO
SCIENTIFIC PROGRAM
November 5th
November 6th
MAIN AUDITORIUM
08:40 – 08:50 Opening remarks
08:50 - 10:30
08:50 - 09:10
09:10 - 09:30
09:30 - 09:50
09:50 - 10:10
PLENARY SESSION - Closing the quality gap
Improving the process of care
Can Surviving Sepsis Campaign bundles help?
Is Brazil a resource limited country?
Expensive new treatments and diagnostics:
how can we afford them?
10:10 - 10:30 Discussion
ROOM 01
CHAIRS: Tom van der Poll (ISF)
Reinaldo Salomão(ILAS)
José Mario Teles (AMIB)
Derek Angus
Philip Dellinger
Flavia Machado
TBD
10:30 - 11:00 COFFEE
11:00 - 12:40
11:00 - 11:20
11:20 - 11:40
11:40 - 12:00
12:00 - 12:20
12:20 - 12:40
PLENARY SESSION - The great fluid dilemmas
Considerations
What should we give – (i) colloid or crystalloid?
What should we give - (ii) balanced or unbalanced?
What amount is safe?
Where next? Can recommendations be made?
Group discussion
Jean-Louis Vincent
Konrad Reinhart
Luciano Azevedo
Gordon Bernard
ALL
08:30 - 10:10 THEMATIC SESSION - Contemporary topics in
clinical management - Part II
08:30 - 08:50 Sepsis coagulopathy: when to treat and when to watch
08:50 - 09:10 Antibiotic stewardship – why, how, when and to whom?
09:10 - 09:30 End-of-life ICU care – an international consensus
09:30 - 09:50 New devices for sepsis
09:50 - 10:10 Immunonutrition: should we bother?
10:10 - 11:00 COFFEE
11:00 - 12:30 PRO/CON - Killing the bug
We must use biomarkers to guide antibiotic duration
11:00 - 11:45 Pro:
Con:
It is time to stop combined antibiotic therapy
for severe sepsis
11:45 - 12:30 Pro:
Con:
12:30 - 14:00
TBD
Steven Opal
Charles Sprung
Phillip Dellinger
Flavia Machado
Jean-Paul Mira
Jorge Salluh
Thiago Lisboa
Thierry Calandra
LUNCH + SATELLITE SYMPOSIUM
12:40 - 14:00 LUNCH + SATELLITE SYMPOSIUM
ROOM 01
ROOM 02
14:00 – 15:40 THEMATIC SESSION - Contemporary topics in
clinical management
14:00 – 14:20 Managing and preventing cerebral dysfunction
14:20 – 14:40 Respiratory end points of resuscitation
14:40 – 15:00 When to start renal replacement therapy
15:00 – 15:20 Hemodynamic end points of resuscitation
15:20 - 15:40 Managing and preventing ICU acquired weakness
08:30 - 10:10
08:30 - 08:50
08:50 - 09:10
09:10 - 09:30
09:30 - 09:50
09:50 - 10:10
10:10 - 11:00
Fernando Bozza
Gordon Bernard
Jean-Paul Mira
Glenn Hernandez
Felipe Dal Pizzol
15:40 - 16:30 COFFEE
11:00 - 11:45 Pro:
Con:
A target mean BP of 65 mmHg is unnecessarily high
11:45 - 12:30 Pro:
Con:
ROOM 02
THEMATIC SESSION - Beyond the typical sepsis bug
Preparing for the next pandemic
Interactions between HIV & sepsis
Meliodosis, TB and other nasties
Interactions between malaria & sepsis
Emerging diseases in a shrinking world
John Marshall
Andre Japiassu
Tom van der Poll
Hugo Castro Faria Neto
Thierry Calandra
15:40 - 16:30 COFFEE
16:30 – 17:00 ORAL PRESENTATIONS – Epidemiology research
ROOM 03
14:00 – 15:40
14:00 – 14:20
14:20 – 14:40
14:40 – 15:00
15:00 – 15:20
15:20 - 15:40
THEMATIC SESSION - Better models of sepsis
In vitro models
Of mice, rats and men
Large animal models: the best choice
In silico models
Human volunteers
John Marshall
Jean-Paul Mira
Derek Angus
Alexandre Biasi
Gordon Bernard
11:00 - 12:30 PRO/CON - Challenging the guidelines
It is unsafe to resuscitate without SvO2
16:30 – 17:00 ORAL PRESENTATIONS – Clinical research
14:00 – 15:40
14:00 – 14:20
14:20 – 14:40
14:40 – 15:00
15:00 – 15:20
15:20 - 15:40
THEMATIC SESSION - Fixing sepsis trials
Designing smarter phase II trials
Theragnostics are the way ahead
Should we use adaptive designs?
Getting away from mortality as an endpoint
Big is beautiful
COFFEE
08:30 - 10:10
08:30 - 08:50
08:50 - 09:10
09:10 - 09:30
09:30 - 09:50
09:50 - 10:10
THEMATIC SESSION - New translations from the lab
The role of heme
Target the neutrophil
Target metabolic-energetic stress
Sepsis: immune exhaustion or immune reprogramming?
New drug development from the biotech/
industry perspective
10:10 - 11:00 COFFEE
15:40 - 16:30 COFFEE
16:30 – 17:00 ORAL PRESENTATIONS – Basic research
12:30 - 14:00
POSTER VIEWING - 17:30 - 19H00
All sections with
simultaneous translations
Charles Sprung
Eliezer Silva
ROOM 03
11:00 - 12:30 PRO/CON - Back from the grave?
We should ban catecholamines
11:00 - 11:45 Pro:
Con:
We need to develop anti-inflammatory therapies
11:45 - 12:30 Pro:
Con:
Hugo Castro Faria Neto
Mervyn Singer
Luciano Azevedo
Mitchell Fink
Tom van der Poll
Phillip Dellinger
Konrad Reinhart
Marcelo Bozza
Fernando Cunha
Mervyn Singer
Reinaldo Salomão
Mitchell Fink
Mervyn Singer
Jean-Louis Vincent
Steven Opal
Fernando Bozza
LUNCH + SATELLITE SYMPOSIUM
MAIN AUDITORIUM
14:00 – 15:40 PLENARY SESSION - Early detection and
Identification of the bug
14:00 – 14:20 Understanding PoC technologies
14:20 – 14:40 Pathogen detection
14:40 – 15:00 Host response detection
15:00 – 15:20 Early markers of organ dysfunction
15:20 - 15:40 Discussion
Steven Opal
Thierry Calandra
Tom van der Poll
Jean-Louis Vincent
15:40 - 16:10 COFFEE
Online registration
www.forumsepse.com.br
16:10 – 17:00
16:10 - 16:25
16:25 - 16:40
16:40 - 16:55
16:55 - 17:10
17:10 - 17:25
17:25 - 17:50
PLENARY SESSION: UPDATE ON CLINICAL TRIALS
The early goal directed therapy trials
Ongoing Canadian trials
Ongoing European trials
Ongoing Industry trials
Ongoing Brazilian trials
The new ARDSnet trial group – PETAL
Derek Angus
John Marshall
Jean-Paul Mira
Steven Opal
Marcio Soares
Gordon Bernard
E
EVENTOS

Similar documents

Sepsis-Specific Treatment Market Will Expand from 2016 and Reach $354 Million by 2021

Sepsis-Specific Treatment Market Will Expand from 2016 and Reach $354 Million by 2021 Following the first sepsis-specific product launch in 2016, the treatment market will expand at a Compound Annual Growth Rate (CAGR) of 69% to reach $354 million by 2021 across the six major markets (6MM) of the US, UK, France, Germany, Italy and Spain, according to research and consulting.

More information